Allosteric Inhibitor Development Targeting HIV‐1 Integrase
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
HIV‐1 integrase (IN) is one of three essential enzymes for viral replication, and is a focus of ardent antiretroviral drug discovery and development efforts. Diligent research has led to the development of the strand‐transfer‐specific chemical class of IN inhibitors, with two compounds from this group, raltegravir and elvitegravir, advancing the farthest in the US Food and Drug Administration (FDA) approval process for any IN inhibitor discovered thus far. Raltegravir, developed by Merck & Co., has been approved by the FDA for HIV‐1 therapy, whereas elvitegravir, developed by Gilead Sciences and Japan Tobacco, has reached phase III clinical trials. Although this is an undoubted success for the HIV‐1 IN drug discovery field, the emergence of HIV‐1 IN strand‐transfer‐specific drug‐resistant viral strains upon clinical use of these compounds is expected. Furthermore, the problem of strand‐transfer‐specific IN drug resistance will be exacerbated by the development of cross‐resistant viral strains due to an overlapping binding orientation at the IN active site and an equivalent inhibitory mechanism for the two compounds. This inevitability will result in no available IN‐targeted therapeutic options for HIV‐1 treatment‐experienced patients. The development of allosterically targeted IN inhibitors presents an extremely advantageous approach for the discovery of compounds effective against IN strand‐transfer drug‐resistant viral strains, and would likely show synergy with all available FDA‐approved antiretroviral HIV‐1 therapeutics, including the IN strand‐transfer‐specific compounds. Herein we review the concept of allosteric IN inhibition, and the small molecules that have been investigated to bind non‐active‐site regions to inhibit IN function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
An essential role for LEDGF/p75 in HIV integration
Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., Teo, W., & Poeschla, E. M. (2006) · Science · doi:10.1126/science.1132319 · Cited by 537
Engelman, A., & Craigie, R. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6361-6369.1992 · Cited by 519
LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493
Johnson, M. S., McClure, M. A., Feng, D. F., Gray, J., & Doolittle, R. F. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.20.7648 · Cited by 480
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
Engelman, A., Englund, G., Orenstein, J. M., Martin, M. A., & Craigie, R. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2729-2736.1995 · Cited by 445
Bushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408
Chen, J. C.-H., Krucinski, J., Miercke, L. J. W., Finer-Moore, J. S., Tang, A. H., Leavitt, A. D., & Stroud, R. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150220297 · Cited by 404
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action
Tsiang, M., Jones, G. S., Niedziela-Majka, A., Kan, E., Lansdon, E. B., Huang, W., Hung, M., Samuel, D., Novikov, N., Xu, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347534 · Cited by 167
“There are multiple approaches to targeting the IN enzyme allosterically for drug development (18).”
BackgroundLEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions
Desimmie, B. A., Schrijvers, R., Demeulemeester, J., Borrenberghs, D., Weydert, C., Thys, W., Vets, S., Van Remoortel, B., Hofkens, J., De Rijck, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-57 · Cited by 139
“[15], and does not refer to the specific and novel mechanism of action of LEDGINs.”
BackgroundSerrao, E., Xu, Z.-L., Debnath, B., Christ, F., Debyser, Z., Long, Y.-Q., & Neamati, N. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.07.047 · Cited by 47
Self-citationDe Luca, L., Morreale, F., Christ, F., Debyser, Z., Ferro, S., & Gitto, R. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.07.025 · Cited by 17
Metadata
- Authors
- Al‐Mawsawi, L. Q., & Neamati, N.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2011-01-12
- Volume
- 6
- Issue
- 2
- Pages
- 228-241
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2041532523
- Cited by
- 61
- References
- 19
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allosteric Inhibitor Development Targeting HIV‐1 Integrase. https://app.cochat.ai/papers/10.1002/cmdc.201000443
- The paper
- Al‐Mawsawi, L. Q., & Neamati, N. (2011). Allosteric Inhibitor Development Targeting HIV‐1 Integrase. ChemMedChem. https://doi.org/10.1002/cmdc.201000443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.